fda-approved and ldts in nsclc proofs 9.7.16 (002)

7

Upload: michael-shea

Post on 13-Apr-2017

9 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

PMOSept16.pdf

Drugs to treat nsclc

Investor deck (fy16 q4) final 9.7.16

LDTS 1 - Vogel Gruppe · SKF Dry Film Lubricant LDTS 1 is specially developed for ... where incidental contact with food cannot be excluded.

Multimodality Treatment Of Stage Iii Nsclc

Brain Metastases in NSCLC Boone Goodgame, MD

Advanced Drug Delivery Reviews - Rice Universitynablab.rice.edu/publications/ADDR_2016.pdf · veloped tests (LDTs) rather than in vitro diagnostics (IVDs), but LDTs have also recently

NSCLC - InOncology · 2020-06-15 · NSCLC, the most common type of lung cancer, is genomically diverse ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; NSCLC,

Immune checkpoint inhibitors in NSCLC - OncologyPRO€¦ · Dxnot approved fordurvalumabin any setting Dxnot approved foravellumabin US/EU: any setting NSQ NSCLC EU: NSQ NSCLC Approved

From Inquiry to Investigation to Insight: Clinical Clarity in … · 2019. 12. 6. · EGFR in NSCLC •10% of NSCLC cases in North America •30%–50% of NSCLC cases in East Asia

New developments of targeted therapy in nsclc

Emerging Treatment Paradigms in NSCLC

Surgical Approach to NSCLC

Predicting NSCLC prognosis by automated pathology

Current standard of care of NSCLC · First TKI versus chemotherapy in EGFR mutated NSCLC. Mok, NEJM 2009. Rosell, Lancet Oncol 2012. First-line TKI therapy in EGFR-mutated NSCLC:

Nsclc slide deck

MadMackenzie GreenZyme Prez_Rev 9.7.16

CCO Metastatic NSCLC Slides

GEN Biomarket Trends Report LDTs Based on Mass Spec

Laboratory Developed Tests (LDTs) and the FDA: The … Developed Tests (LDTs) and the FDA: The Impact on Clinical Laboratories ... Medical Practice • Design • Development

Early Stage Nsclc The Role Of Chemotherapy

Chemo rt in nsclc 2011- jk

Biomarker testing in non- small cell lung cancer (NSCLC) · NSCLC is both histologically and genetically diverse. 3. Prevalence of genetic alterations in NSCLC. 4. 40%. 25%. 10%

Maintenance therapy for NSCLC

The Evolving Treatment Landscape in NSCLC

Nancy Stade Sidley Austin LLP May 4, 2017...marketed as LDTs but are in fact not LDTs are out of compliance with the FD&C Act6; however, in the interest of ensuring continuity in the

Improving Outcomes in Advanced NSCLC with Immune ...•5-year survival rate is 19% (NSCLC + SCLC) •From 2009–2015, the relative survival rate for NSCLC was 25% •Recent overall

Management of NSCLC

NSCLC: Targeted Therapies and Beyond · approved for the treatment of NSCLC. There are also drugs that target specific NSCLC–associated mutations. For example, 10-35 percent of

LungNet: Shallow CNN models for NSCLC

Targeting oncogenic drivers in NSCLC - OncologyPROoncologypro.esmo.org/content/download/98588/1730732/file/ESMO... · Targeting oncogenic drivers in NSCLC ... ETOP sponsored,

Emerging Targets for Squamous Cell NSCLC

Tratamiento TKI-estudio IFUM NSCLC

Treatment of ALK Positive Advanced NSCLC · Treatment of ALK Positive Advanced NSCLC ... • First identified in NSCLC cells in 2007 ... Chemistry of ALK Tyrosine Kinase Inhibitors